openalexFrontiers in Immunology2026-07-24
Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases
Francisco J. Fernández, Lucía Alfonso‐González, Manuel Praga, Kaare Mikkelsen, M. Cristina Vega
Eculizumab, a humanized monoclonal antibody targeting the complement protein C5, is highly efficient in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. However, recent reports have…